• Patients, Supporters Worldwide Recognizing Rare Disease Day 2020
  • Fintepla Daily Significantly Lowers Seizures in Young Dravet Patients, Trial Data Show
  • Epygenix Advancing EPX-100 to Phase 2 Trial in Dravet Patients, Based on Positive Phase 1 Results
  • FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar
  • With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus
  • FDA Approves Valtoco Nasal Spray to Treat Seizure Clusters in Epilepsy Patients, 6 and Older
  • Behind the Seizure Program Expands Access to Free Genetic Testing for Children Under 8
  • Stoke’s STK-001 Prolongs Survival, Reduces Seizures in Dravet Mouse Model, Preclinical Study Shows
  • U.K. Physicians Now Can Prescribe Epidyolex Cannabidiol Solution to Treat Dravet, LGS Patients
  • Febrile Seizures After Vaccination May Indicate Dravet, Study Shows
  • Gene Therapy Takes Center Stage at 2019 NORD Summit
  • HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases